Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A tetrahydro-naphthalenyl derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:



(I)

wherein

R^1 represents hydrogen or C_{1-6} alkyl;

X represents $-N(H)Y^1$, $-N(H)-C_{1-6}$ alkyleneY^1, biphenyl or C_{1-6} alkyl substituted by biphenyl;

wherein

said biphenyl is substituted by Z^1, Z^2 ~~and~~ or Z^3;

Y^1 represents biphenyl substituted by Z^3, Z^4 ~~and~~ or Z^5;

Z^1 and Z^2 are identical or different and represent hydrogen, halogen, carboxy, nitro, C_{1-6} alkyl optionally substituted by cyano or mono-,

di-, or tri- halogen, C_{1-6} alkoxy optionally substituted by morpholino, or mono-, di-, or tri- halogen, C_{1-6} alkylthio, amino, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, C_{1-6} alkylsulfinyl, C_{1-6} alkanoyl, or C_{1-6} alkoxycarbonyl;

Z^3 represents hydrogen, halogen, amino, pyrrolidinyl, piperidino, piperazinyl, homopiperidino, C_{1-6} alkoxy optionally substituted by mono-, di-, or tri- halogen, or C_{1-6} alkyl optionally substituted by mono-, di-, or tri- halogen;

Z^4 represents halogen, carboxy, nitro, C_{1-6} alkyl optionally substituted by cyano or mono-, di-, or tri- halogen, C_{1-6} alkoxy optionally substituted by morpholino, or mono-, di-, or tri- halogen, C_{1-6} alkylthio, amino, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, C_{1-6} alkylsulfinyl, C_{1-6} alkanoyl, or C_{1-6} alkoxycarbonyl; and

Z^5 represents hydrogen, halogen, carboxy, nitro, C_{1-6} alkyl optionally substituted by cyano or mono-, di-, or tri- halogen, C_{1-6} alkoxy optionally substituted by morpholino, or mono-, di-, or tri- halogen, C_{1-6} alkylthio, amino, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, C_{1-6} alkylsulfinyl, C_{1-6} alkanoyl, or C_{1-6} alkoxycarbonyl;

or

Z^4 and Z^5 together with the carbon atom to which they are attached, form a benzene ring.

2. (Original) The tetrahydro-naphthalenyl derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

R^1 represents hydrogen;

X represents $-N(H)Y^1$ or $-N(H)-C_{1-6}$ alkyleneY^1;

Y^1 represents



;

Z^3 represents hydrogen, fluoro, chloro, bromo, amino, pyrrolidinyl, piperidino, piperazinyl, homopiperidino, C_{1-6} alkoxy optionally substituted by cyano or mono-, di-, or tri- halogen, or C_{1-6} alkyl optionally substituted by cyano or mono-, di-, or tri- halogen;

Z^4 represents halogen, carboxy, nitro, C_{1-6} alkyl optionally substituted by cyano or mono-, di-, or tri- halogen, C_{1-6} alkoxy optionally substituted by morpholino, or mono-, di-, or tri- halogen, C_{1-6} alkylthio, amino, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, C_{1-6} alkylsulfinyl, C_{1-6} alkanoyl, or C_{1-6} alkoxycarbonyl; and

Z^5 represents hydrogen, halogen, carboxy, nitro, C_{1-6} alkyl optionally substituted by cyano or mono-, di-, or tri- halogen, C_{1-6} alkoxy

optionally substituted by morpholino, or mono-, di-, or tri- halogen, C_{1-6} alkylthio, amino, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, C_{1-6} alkylsulfinyl, C_{1-6} alkanoyl, or C_{1-6} alkoxycarbonyl.

3. (Original) The tetrahydro-naphthalenyl derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

R^1 represents hydrogen;

X represents $-N(H)Y^1$ or $-N(H)-C_{1-6}$ alkyleneY^1;

Y^1 represents



;

Z^3 represents hydrogen or piperidino;

Z^4 represents fluoro, chloro, bromo, carboxy, nitro, C_{1-6} alkyl optionally substituted by mono-, di-, or tri- halogen, C_{1-6} alkoxy optionally substituted by morpholino, or mono-, di-, or tri- halogen, C_{1-6} alkylthio, di(C_{1-6} alkyl)amino, C_{1-6} alkylsulfinyl, C_{1-6} alkanoyl, or C_{1-6} alkoxycarbonyl; and

Z^5 represents hydrogen, fluoro, chloro, bromo, C_{1-6} alkoxy, C_{1-6} alkylthio or C_{1-6} alkyl optionally substituted by cyano or mono-, di-, or tri- halogen.

4. (Original) The tetrahydro-naphthalenyl derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

R^1 represents hydrogen;

X represents



;

n represents an integer selected from 0 to 6;

Z^1 and Z^2 are identical or different and represent hydrogen, fluoro, chloro, bromo, carboxy, nitro, C_{1-6} alkyl optionally substituted by mono-, di-, or tri- halogen, C_{1-6} alkoxy optionally substituted by morpholino, or mono-, di-, or tri- halogen, C_{1-6} alkylthio, di(C_{1-6} alkyl)amino, C_{1-6} alkylsulfinyl, C_{1-6} alkanoyl, or C_{1-6} alkoxycarbonyl; and

Z^3 represents hydrogen, fluoro, chloro, bromo, amino, piperidino, C_{1-6} alkoxy optionally substituted by mono-, di-, or tri- halogen, or C_{1-6} alkyl optionally substituted by cyano or mono-, di-, or tri- halogen.

5. (Original) The tetrahydro-naphthalenyl derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,
wherein

R^1 represents hydrogen;

X represents



;

n represents an integer of 0 or 1;

Z^1 represents hydrogen, fluoro, chloro, bromo, C_{1-6}alkyl, C_{1-6} alkoxy, amino, C_{1-6} alkylamino, or di(C_{1-6} alkyl)amino;

Z^2 represents hydrogen, fluoro, chloro, bromo, C_{1-6} alkyl or C_{1-6} alkoxy: and

Z^3 represents hydrogen.

6. (Currently amended) The tetrahydro-naphthalenyl derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1, wherein said tetrahydro-naphthalenyl derivative of the formula (I) is selected from the group consisting of:

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[4'-(trifluoromethyl)-biphenyl-3-yl]urea;
N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[2'-(trifluoromethyl)-biphenyl-3-yl]urea;
N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[4'-(methylthio)-biphenyl-3-yl]urea;
N-(2',3'-dichlorobiphenyl-3-yl)-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;
N-(2',4'-dichlorobiphenyl-3-yl)-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;
N-(4'-acetylbiphenyl-3-yl)-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;
N-[(2'-fluorobiphenyl-4-yl)methyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;
~~N-[(2'-fluorobiphenyl-4-yl)methyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;~~
N-[(2',6'-difluorobiphenyl-4-yl)methyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;
N-[(2'-fluorobiphenyl-3-yl)methyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;
N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[(4'-isopropylbiphenyl-3-yl)methyl]urea; and
N-[(2',4'-dichlorobiphenyl-3-yl)methyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea.

7. (Currently amended) A ~~medicament~~ pharmaceutical composition comprising a tetrahydro-naphthalene derivative of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1 ~~in~~ as an active ingredient , plus a pharmaceutically acceptable carrier.

8. (Cancelled)

9. (Currently amended) The ~~medicament~~ pharmaceutical composition as claimed in claim 7, wherein said tetrahydro-naphthalene derivative of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof is a VR1 antagonist.

10. (Cancelled)

11. (Cancelled)

12. (Cancelled).

13. (Cancelled)

14. (Cancelled)

15. (Cancelled)

16. (Cancelled)

17. (Cancelled)

18. (Cancelled)

19. (Cancelled)

20. (Cancelled)

21. (Currently amended) ~~Process~~ A process for controlling ~~an~~ a urological disorder or disease in humans and animals ~~by administration of~~ comprising administering a VR1-antagonisticly effective amount of at lease one compound according to claim 1.

22. (Currently amended) ~~Process~~ A process for controlling pain in humans and animals ~~by administration of~~ comprising administering a VR1-antagonisticly effective amount of at least one compound according to claim 1.

23. (Currently amended) ~~Process~~ A process for controlling an inflammatory disorder or disease in humans and animals ~~by administration of~~ comprising administering a VR1-antagonisticly effective amount of at least one compound according to claim 1.

24. (New) A method for treatment and/or prophylaxis of a urological disorder in a human or animal, said urological disorder being selected from uninary incontinence, overactive bladder, and urge urinary incontinence, comprising administering to a patient in need thereof an effective amount of a compound of claim 1.

25. (New) A method for treatment and/or control of a painful condition in a human or animal, said painful condition being selected from chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia,, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, and stroke, comprising administering to a patient in need thereof an effective amount of a compound of claim 1.

26. (New) A method for treatment and/or prophylaxis of an inflammatory disorder in a human or animal, said inflammatory disorder being selected from asthma and COPD, comprising administering to a patient in need thereof an effective amount of a compound of claim 1.